The Front Line COVID-19 Critical Care Alliance (FLCCC) has issued a public response to the National Institutes of Health (NIH) regarding the NIH COVID-19 Treatment Guidelines Panel’s “neither for nor against” recommendation for the use of ivermectin in the treatment of COVID-19.
- According to the FLCCC, the NIH Treatment Guidelines Panel should have given ivermectin a more specific recommendation for use as a therapeutic for COVID-19 because of the Randomized Controlled Trials (RCTs) that demonstrated high magnitude improvements in clinical recovery, mortality rates and prevention.
- The NIH’s statement that they are awaiting “adequately powered, well-designed, and well-conducted clinical trials” before providing more specific guidance is confounding since it clearly disregards the scientific importance of the objective and reproducible findings in 32 controlled trials conducted in countries throughout the world—20 of which are RCTs.
- Numerous groups from around the world have concluded that ivermectin is a highly effective therapy for COVID-19 and should be widely adopted for use. Yet the NIH panel diverges from other expert groups and expert peer reviewers who have accepted the FLCCC’s scientific manuscript and its conclusions for publication.
The full FLCCC response is HERE.
Media: For further information or to arrange for an interview, please email press@flccc.net.
